Skip Navigation

NCI-COG Pediatric MATCH Molecular Analysis for Therapy Choice - Phase 2 Subprotocol of BVD-523FB Ulixertinib in Patients with Tumors Harboring Activating MAPK Pathway Mutations

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03698994

Study #:
CMH - APEC1621J

Start Date:
Oct 10, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03698994

View Complete Trial Details & Eligibility at ClinicalTrials.gov